

Article

Not peer-reviewed version

---

# New Pyranone Derivatives and Sesquiterpenoid Isolated from the Endophytic Fungus *Xylaria* sp. Z184

---

Yan Zhang , Yang Jin , Wensi Yan , Peishan Gu , Ziqian Zeng , Ziying Li , [Guangtao Zhang](#) , [Mi Wei](#) , [Yongbo Xue](#) \*

Posted Date: 8 April 2024

doi: 10.20944/preprints202404.0478.v1

Keywords: *Xylaria* sp.; pyranone derivative; sesquiterpenoid; antimicrobial activity



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

# New Pyranone Derivatives and Sesquiterpenoid Isolated from the Endophytic Fungus *Xylaria* sp. Z184

Yan Zhang <sup>1,†</sup>, Yang Jin <sup>1,†</sup>, Wensi Yan <sup>1</sup>, Peishan Gu <sup>1</sup>, Ziqian Zeng <sup>1</sup>, Ziying Li <sup>2</sup>, Guangtao Zhang <sup>2</sup>, Mi Wei <sup>3</sup> and Yongbo Xue <sup>1,\*</sup>

<sup>1</sup> School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, P. R. China

<sup>2</sup> School of Pharmacy, Binzhou Medical University

<sup>3</sup> School of Agriculture, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, P. R. China

\* Correspondence: xueyb@mail.sysu.edu.cn

† Yan Zhang and Yang Jin contributed equally to this work.

**Abstract:** The fungus *Xylaria* sp. Z184, harvested from the leaves of *Fallopia convolvulus* (L.) Á. Löve, has been isolated for the first time. Chemical investigation on the methanol extract of the culture broth of the titles strain led to the discovery of three new pyranone derivatives, called fallopiaxyllaresters A–C (1–3), and a new bisabolane-type sesquiterpenoid, named fallopiaxyllarol A (4), along with the first complete set of spectroscopic data for the previously-reported pestalotiopyrone M (5). Known pyranone derivatives (6–11), sesquiterpenoids (12–14), isocoumarin derivatives (15–17), and an aromatic allenic ether (18) were also co-isolated in this study. All new structures were elucidated by the interpretation of HRESIMS, 1D, 2D NMR spectroscopy, and quantum chemical computation approach. The *in vitro* antimicrobial, anti-inflammatory, and  $\alpha$ -glucosidase inhibitory activities of the selected compounds and the crude extract were evaluated. The extract was inhibited nitric oxide (NO) production induced by lipopolysaccharide (LPS) in murine RAW264.7 macrophage cells, with an inhibition rate of  $77.28 \pm 0.82\%$  at a concentration of 50  $\mu$ g/mL. The compounds 5, 7, and 8 displayed weak antibacterial activity against *Staphylococcus aureus* subsp. *aureus* at a concentration of 100  $\mu$ M.

**Keywords:** *Xylaria* sp.; pyranone derivative; sesquiterpenoid; antimicrobial activity


## 1. Introduction

Natural products (NPs) have always been an indispensable source of new drugs [1]. As an important source of NPs with novel structures and high-value biological activities, plant endophytic fungi always attracted broad attentions from natural product chemists and pharmacologists [2,3]. Xylariaceae is one of the largest, most commonly encountered, and highly diverse fungal families of the Ascomycota [4]. The genus *Xylaria*, belonging to the family Xylariaceae, is medicinal fungi commonly found in decaying plant tissues and is widely distributed in temperate, tropical, and subtropical regions [5,6]. So far, more than two hundred bioactive compounds ( $> 100$  new ones) were isolated from *Xylaria*, including cytochalasins,  $\alpha$ -pyrones, cyclopeptides, terpenoids, lactones, and succinic acid derivatives [7]. Besides, the secondary metabolites produced by species of *Xylaria* were found to exert wide range of biological activities, such as anti-inflammatory, antifungal, antibacterial, anti-tumor, and  $\alpha$ -glucosidase inhibitory activities [7,8].

As part of our group's ongoing effort to identify bioactive natural products from medicinal plants and endophytic fungi [9–11], the fungus *Xylaria* sp. Z184, isolated from the leaves of *Fallopia convolvulus* (L.) Á. Löve for the first time, has attracted our attention for its impressive compound abundance in TLC and HPLC analyses (Figure). Our current investigation on this strain led to the isolation of three new pyranone derivatives, called fallopiaxyllaresters A–C (1–3), a new bisabolane-type sesquiterpenoid fallopiaxyllarol A (4) (Figure 1), and the first complete set of the spectroscopic data for the previously-disclosed pestalotiopyrone M (5), as well as a suite of known compounds consisting of six pyranone derivatives (6–11), three sesquiterpenoids (12–14), three isocoumarin



derivatives (**15–17**), and one aromatic allenic ether (**18**). Herein, the details of the isolation, structure elucidation of all new compounds and their anti-inflammatory, anti-microbial, and  $\alpha$ -glucosidase inhibitory activities were described.



**Figure 1.** Chemical structures of compounds **1–18**.

## 2. Results and Discussion


Compound **1**, named fallopiaxylarester A, was obtained as a white solid. Its molecular formula  $C_{12}H_{16}O_6$  was determined by the HRESIMS molecular ion peak at  $m/z$  279.0837 [ $M + Na$ ]<sup>+</sup> (calcd for  $C_{12}H_{16}O_6Na$ , 279.0839). The IR absorption bands showed the presence of hydroxyl ( $3426\text{ cm}^{-1}$ ) and carbonyl ( $1733\text{ cm}^{-1}$ ) functionalities. Detailed comparison of <sup>1</sup>H and <sup>13</sup>C NMR spectra of **1** and **10** revealed that structure of **1** is almost identical with that of **10**, which was supported by the further analysis of 2D NMR spectra (Table 1). The HMBC correlations of **1** from H-2 ( $\delta_H$  5.56) to C-1/C-3/C-4, from H<sub>3</sub>-12 ( $\delta_H$  3.87) to C-3, from H-4 ( $\delta_H$  6.22) to C-3/C-5/C-6, from H-6 ( $\delta_H$  4.35) to C-5 and C-8, showed the same settlement with compound **10** (Figure 2). The main difference between **1** and **10** was found at C-10 of the side chain of the pyranone core, replaced by the fragment of methyl valerate group. This deduction was further identified by the HMBC correlations from H<sub>3</sub>-11 ( $\delta_H$  3.66) and H<sub>2</sub>-9 ( $\delta_H$  2.38) to C-10. Thus, the planar structure of **1** was established. Since there was only one chiral center in the molecule, the relative configuration was arbitrarily assigned as 6R\*. The absolute configuration of C-6 was subsequently assigned to be R by comparing the optical rotational value  $[\alpha]_D^{25} +56.2$  (*c* 0.11, MeOH) with  $[\alpha]_D^{25} +96.0$  (*c* 0.10, MeOH) of compound **10** [12]. Besides, the deduction was also confirmed by a time-dependent density functional theory-electronic circular dichroism (TDDFT-ECD) approach. As shown in Figure 3, the Boltzmann-averaged ECD spectrum of (6R)-**1** displayed a similar curve compared to the experimental one. Thus, the absolute configuration at C-6 in **1** was unambiguously assigned as 6R (Figure 1).

Compound **2**, a white solid, was determined to possess the molecular formula of  $C_{19}H_{28}O_9$  with six degrees of unsaturation by using HRESIMS ( $m/z$  423.1626 [ $M + Na$ ]<sup>+</sup>, (calcd for  $C_{19}H_{28}O_9Na$ , 423.1626)). The spectra of **2** showed the similar absorption bands, indicating the same presence of hydroxyl ( $3359\text{ cm}^{-1}$ ) and carbonyl ( $1696\text{ cm}^{-1}$ ) functionalities. The <sup>1</sup>H NMR spectra (Table 2) data showed signals of a typical sugar moiety at  $\delta_H$  5.12 (d,  $J = 3.7\text{ Hz}$ ), 3.53 (dd,  $J = 10.0, 3.7\text{ Hz}$ ), 3.78 (t,  $J = 9.3\text{ Hz}$ ), 3.45 (t,  $J = 9.3\text{ Hz}$ ), 3.90 (m), and 3.76 (m). Analysis of the <sup>13</sup>C NMR and DEPT spectra of **2** indicated the presence of 19 carbon signals, assignable to two methyl carbons (one methoxyl,  $\delta_C$  57.0 and 14.4), five methylene carbons ( $\delta_C$  27.1, 30.0, 32.8, 23.6 and 62.1), eight methine carbons (three olefinic,  $\delta_C$  89.4, 100.2, 125.0, 102.8, 73.4, 74.4, 71.0, and 75.5), one ester carbonyl carbon ( $\delta_C$  166.7), and three olefinic quaternary carbons ( $\delta_C$  174.0, 157.9 and 145.8). These substructures accounted for four out of five


degrees of unsaturation, indicating one cyclic system in **2**. The  $^1\text{H}$ - $^1\text{H}$  COSY spectrum revealed three spin systems: (a) H-7/H-8/H-9; (b) H-11/H-12 and (c) H-1'/H-2'/H-3'/H-4'/H-5'/H-6' (Figure 2). And those spin systems were connected by the key HMBC correlations from H-2 ( $\delta_{\text{H}}$  5.59) to C-1/C-3/C-4, from H<sub>3</sub>-13 ( $\delta_{\text{H}}$  3.87) to C-3, from H-4 ( $\delta_{\text{H}}$  6.95) to C-3/C-5/C-6, from H-7 ( $\delta_{\text{H}}$  6.07) to C-5, and from H<sub>2</sub>-9 ( $\delta_{\text{H}}$  1.48) to C-10/C-11.

**Table 1.**  $^1\text{H}$  NMR ( $\delta_{\text{H}}$ , 600 MHz) and  $^{13}\text{C}$  NMR ( $\delta_{\text{C}}$ , 150 MHz) data for **1** in methanol- $d_4$ .

No.	$\delta_{\text{H}}$ , mult (J Hz)	$\delta_{\text{C}}$ , Type
1		167.0, C
2	5.56, d (2.1)	88.6, CH
3		173.8, C
4	6.22, d (2.1)	99.9, CH
5		168.7, C
6	4.35, dd (7.2, 4.8)	70.7, CH
7	1.83, m 1.68, m, overlap	35.2, CH <sub>2</sub>
8	1.76, m 1.69, m, overlap	21.7, CH <sub>2</sub>
9	2.38, t (6.7)	34.4, CH <sub>2</sub>
10		175.6, C
11	3.66, s	52.0, CH <sub>3</sub>
12	3.87, s	57.0, CH <sub>3</sub>




**Figure 2.** The key  $^1\text{H}$ - $^1\text{H}$  COSY and HMBC correlations of **1–4**.



**Figure 3.** Experimental ECD spectrum of fallopiaxylarester A (**1**) (black); calculated ECD of (6R)-1 (red); mirrored spectrum of calculated ECD (blue).

Subsequently, the long range HMBC correlation from H-1' ( $\delta_H$  5.12) to the anomeric carbon C-6 suggested the sugar was attached at C-6 of the side chain. Acid hydrolysis of **2** followed by HPLC analysis of the sugar derivative was applied to determine the type of sugar moiety but without success. Then, different deuterated solvent, pyridine-*d*<sub>5</sub>, was used to analyze the proton signals on the sugar. Besides, the isolated anomeric proton signal was probed by a selective 1D-TOCSY experiment. In the 1D-TOCSY experiment, irradiation of the signal at  $\delta_H$  5.68 (1H, d, *J* = 3.7 Hz) enabled the identification of H-2' ( $\delta_H$  4.27, dd, *J* = 10.5, 4.1 Hz), H-3' ( $\delta_H$  4.71, t, *J* = 9.3 Hz), H-4' ( $\delta_H$  4.35, t, *J* = 10.0 Hz), H-5' ( $\delta_H$  4.66, dt, *J* = 10.0, 3.5 Hz), H<sub>2</sub>-6' ( $\delta_H$  4.48, br s) in the same conjugated system (Figure 4, Table 2). The *J* values of  $J_{H-5'/H-4'}$  (10.0 Hz) and  $J_{H-5'/H-6'}$  (3.5 Hz) in <sup>1</sup>H NMR in pyridine-*d*<sub>5</sub> of **2** combined with the 1D-TOCSY experiment suggested an  $\alpha$ -D-glucose. Besides, those chemical shift values of anomeric carbon at  $\delta_C$  102.8 (C-1'), four tertiary carbons at  $\delta_C$  73.4 (C-2'), 74.4 (C-3'), 71.0 (C-4'), 75.5 (C-5'), and a methylene oxide carbon at  $\delta_C$  62.1 (C-6') in methanol-*d*<sub>4</sub> was highly similar to 6-Buty-AA-2G along with other derivatives of AA-2G in the literature [13], which also confirmed the inference that the sugar unit was  $\alpha$ -D-glucose. Besides, the geometry of the double bond between C-6 and C-7 was inferred by the ROESY spectrum in DMSO-*d*<sub>6</sub>. The ROESY correlations between H<sub>2</sub>-8 ( $\delta_H$  2.33) and H-1' ( $\delta_H$  4.96)/H-3' ( $\delta_H$  3.70)/H-5' ( $\delta_H$  3.54), and between H-4 ( $\delta_H$  6.98) and H-1'/H-3' demonstrated the Z geometry of  $\Delta^{6,7}$  (Figs. 5 and S15). Thus, this undescribed **2** was established as shown in Figure 1 and named fallopiaxylarester B.




**Figure 4.** 1D-TOCSY spectra of compounds **2** (purple) and **3** (green).**Table 2.**  $^1\text{H}$  NMR ( $\delta_{\text{H}}$ , 600 MHz) and  $^{13}\text{C}$  NMR ( $\delta_{\text{C}}$ , 150 MHz) data for **2**.

No.	$\delta_{\text{H}}$ , mult (J Hz) <sup>a</sup>	$\delta_{\text{C}}$ , Type <sup>a</sup>	$\delta_{\text{H}}$ , mult (J Hz) <sup>b</sup>	$\delta_{\text{C}}$ , Type <sup>b</sup>	$\delta_{\text{H}}$ , mult (J Hz) <sup>c</sup>	$\delta_{\text{C}}$ , Type <sup>c</sup>
1		166.7, C		164.1, C		162.7, C
2	5.59, d (2.2)	89.4, CH	5.70, d (2.2)	89.7, CH	5.61, d (2.2)	88.6, CH
3		174.0, C		172.3, C		171.2, C
4	6.95, d (2.2)	100.2, CH	7.64, d (2.2)	99.7, CH	6.98, d (2.2)	98.3, CH
5		157.9, C		157.5 C		155.8, C
6		145.8, C		146.1, CH		144.3, C
7	6.07, t (7.5)	125.0, CH	6.24, t (7.5)	123.6, CH	5.91, t (7.5)	122.8, CH
8	2.42, m	27.1, CH <sub>2</sub>	2.61, q (7.5)	26.9, CH <sub>2</sub>	2.33, dd (15.0, 7.6)	25.3, CH <sub>2</sub>
9	1.48, m	30.0, CH <sub>2</sub>	1.33, m	29.7, CH <sub>2</sub>	1.39, m	28.4, CH <sub>2</sub>
10	1.36, m, overlap	32.8, CH <sub>2</sub>	1.19, m, overlap	32.3, CH <sub>2</sub>	1.28, m, overlap	31.1, CH <sub>2</sub>
11	1.37, m, overlap	23.6, CH <sub>2</sub>	1.18, m, overlap	23.2, CH <sub>2</sub>	1.29, m, overlap	22.0, CH <sub>2</sub>
12	0.92, t (6.9)	14.4, CH <sub>3</sub>	0.75, t (7.0)	14.6, CH <sub>3</sub>	0.87, t (6.9)	13.9, CH <sub>3</sub>
13	3.87, s	57.0, CH <sub>3</sub>	3.60, s	56.5, CH <sub>3</sub>	3.81, s	56.4, CH <sub>3</sub>
1'	5.12, d (3.7)	102.8, CH	5.68, d (3.7)	103.4, CH	4.96, d (3.7)	101.3, CH
2'	3.53, dd (10.0, 3.7)	73.4, CH	4.27, dd (10.5, 4.1)	74.0, CH	3.32, m, overlap	71.7, CH
3'	3.78, t (9.3)	74.4, CH	4.71, t (9.3)	75.2, CH	3.70, m	72.5, CH
4'	3.45, t (9.3)	71.0, CH	4.35, t (10.0)	71.9, CH	3.22, m	69.4, CH
5'	3.90, m	75.5, CH	4.66, dt (10.0, 3.5)	76.8, CH	3.54, m, overlap	74.7, CH
6'	3.76, m	62.1, CH <sub>2</sub>	4.48, br s	62.9, CH <sub>2</sub>	3.55, m, overlap	60.3, CH <sub>2</sub>
2'-OH					5.52, d (4.9)	
3'-OH					5.10, m	
4'-OH					5.10, m	
6'-OH					4.53, t (5.8)	

<sup>a</sup>Measured in methanol-*d*<sub>4</sub>, <sup>b</sup>measured in pyridine-*d*<sub>5</sub>, <sup>c</sup>measured in DMSO-*d*<sub>6</sub>.

Compound **3**, named fallopiaxylarester C, was isolated as a white solid. Its molecular formula of C<sub>19</sub>H<sub>30</sub>O<sub>9</sub> with five degrees of unsaturation was based on HRESIMS analysis {*m/z* 425.1780 [M + Na]<sup>+</sup>, (calcd for C<sub>19</sub>H<sub>30</sub>O<sub>9</sub>Na, 425.1782)}. Like **2**, the presence of  $\alpha$ ,  $\beta$ -unsaturated  $\gamma$ -lactone and hydroxyl groups in **3** was obvious by its IR absorption bands at  $\nu_{\text{max}}$  3380, and 1700 cm<sup>-1</sup>. Besides, with the analysis of 1D NMR spectra, a sugar moiety in **3** was also quickly recognized. Besides, the HMBC correlation from H-6 ( $\delta_{\text{H}}$  4.52) to C-1' suggested the same set with **2**. The main difference between these two compounds was the hydrogenation of the trisubstituted olefinic group at C-6/C-7 in **2**, according to 2 mass unit difference between **2** and **3**. Subsequently, an acid hydrolysis of **3** afforded the products including a pyrone aglycone **3a** and a sugar moiety **3b**. The absolute configuration of C-6 in **3a** was assigned to be *R* form by comparing its optical value  $[\alpha]_{\text{D}}^{25}$  +52.5 (*c* 0.11, MeOH) with +67.6 (*c* 0.25, MeOH) of nodulisporipyrone A [14]. According to the detailed analysis of  $^1\text{H}$  NMR and 1D-TOCSY experiment of **3**, H-1' ( $\delta_{\text{H}}$  5.42, d, *J* = 3.8 Hz), H-2' ( $\delta_{\text{H}}$  4.22, dd, *J* = 9.6, 3.8 Hz), H-3' ( $\delta_{\text{H}}$  4.67, t, *J* = 9.6 Hz), H-4' ( $\delta_{\text{H}}$  4.24, t, *J* = 9.6 Hz), H-5' ( $\delta_{\text{H}}$  4.44, t, *J* = 9.6 Hz), H<sub>2</sub>-6' ( $\delta_{\text{H}}$  4.57, dd, *J* = 9.6, 5.6 Hz;  $\delta_{\text{H}}$  4.43, m), the sugar moiety was indicated as  $\alpha$ -D-glucose (Figure 4, Table 3). Moreover, large similarities were observed by comparison of NMR data in DMSO-*d*<sub>6</sub> of **3** with 5-( $\alpha$ -D-glucopyranosyloxymethyl)-2-furancarboxylic acid and other analogs in the literature [15]. Thus, the structure of **3** was established as shown (Figure 1).



**Figure 5.** Energy-minimized structures of **2** and **4** with the key ROESY correlations.

**Table 3.**  $^1\text{H}$  NMR ( $\delta_{\text{H}}$ , 600 MHz) and  $^{13}\text{C}$  NMR ( $\delta_{\text{C}}$ , 150 MHz) data for **3**.

No.	$\delta_{\text{H}}$ , mult (J Hz) <sup>a</sup>	$\delta_{\text{C}}$ , Type <sup>a</sup>	$\delta_{\text{H}}$ , mult (J Hz) <sup>b</sup>	$\delta_{\text{C}}$ , Type <sup>b</sup>	$\delta_{\text{H}}$ , mult (J Hz) <sup>c</sup>	$\delta_{\text{C}}$ , Type <sup>c</sup>
1		167.1, C			164.5, C	164.2, C
2	5.57, d (2.2)	89.1, CH	5.68, d (2.3)	89.1, CH	5.57, d (2.2)	88.0, CH
3		173.6, C			171.9, C	170.9, C
4	6.55, d (2.2)	101.9, CH	6.99, d (2.3)	100.5, CH	6.50, d (2.2)	99.4, CH
5		165.5, C			165.8, C	163.3, C
6	4.52, t (6.2)	75.3, CH	4.82, dd (7.8, 4.4)	74.8, CH	4.38, dd (6.8, 4.8)	72.9, CH
7	1.85, dd (14.0, 7.6)	35.1, CH <sub>2</sub>	1.89, m	35.2, CH <sub>2</sub>	1.70, m	33.5, CH <sub>2</sub>
8	1.43, m	26.2, CH <sub>2</sub>	1.51, m	26.2, CH <sub>2</sub>	1.32, m	24.4, CH <sub>2</sub>
9	1.35, m 1.33, m	30.1, CH <sub>2</sub>	1.18, m, overlap 1.10, m, overlap	29.7, CH <sub>2</sub>	1.27, m, overlap	28.4, CH <sub>2</sub>
10	1.31, m, overlap	32.8, CH <sub>2</sub>	1.08, m, overlap	32.2, CH <sub>2</sub>	1.23, m, overlap	31.1, CH <sub>2</sub>
11	1.32, m, overlap	23.7, CH <sub>2</sub>	1.16, m, overlap	23.3, CH <sub>2</sub>	1.25, m, overlap	22.0, CH <sub>2</sub>
12	0.90, t (6.8)	14.4, CH <sub>3</sub>	0.78, t (7.3)	14.7, CH <sub>3</sub>	0.85, t (6.8)	14.0, CH <sub>3</sub>
13	3.87, s	57.0, CH <sub>3</sub>	3.63, s	56.4, CH <sub>3</sub>	3.81, s	56.4, CH <sub>3</sub>
1'	4.80, d (3.8)	98.5, CH	5.42, d (3.8)	99.3, CH	4.66, d (3.8)	97.2, CH
2'	3.41, dd (9.8, 3.8)	73.2, CH	4.22, dd (9.6, 3.8)	74.0, CH	3.22, m	71.5, CH
3'	3.68, m, overlap	74.8, CH	4.67, t (9.6)	75.6, CH	3.45, m, overlap	73.7, CH
4'	3.29, m	71.7, CH	4.24, t (9.6)	72.6, CH	3.07, m	70.1, CH
5'	3.68, m, overlap	74.6, CH	4.44, t (9.6)	75.8, CH	3.45, m, overlap	73.0, CH
6'	3.68, m, overlap 3.83, m	62.7, CH <sub>2</sub>	4.57, dd (9.6, 5.6) 4.43, m	63.3, CH <sub>2</sub>	3.61, m 3.45, m, overlap	60.9, CH <sub>2</sub> 5.04, d (5.9)
2'-OH					4.92, d (4.1)	
3'-OH					4.99, d (5.2)	
4'-OH					4.52, t (5.4)	
6'-OH						

<sup>a</sup>Measured in methanol-*d*<sub>4</sub>, <sup>b</sup>measured in pyridine-*d*<sub>5</sub>, <sup>c</sup>measured in DMSO-*d*<sub>6</sub>.

Compound **4** was isolated as a colorless oil. Its molecular formula of  $\text{C}_{16}\text{H}_{28}\text{O}_5$  with three degrees of unsaturation was also based on HRESIMS analysis  $\{m/z\} 323.1829 [\text{M} + \text{Na}]^+$ , (calcd for  $\text{C}_{16}\text{H}_{28}\text{O}_5\text{Na}$ , 323.1829). The IR spectrum of **4** demonstrated characteristic absorption bands for hydroxyl ( $3425\text{ cm}^{-1}$ ) and carbonyl ( $1687\text{ cm}^{-1}$ ) groups. The 1D NMR and HSQC spectra of **4** revealed 16 carbon signals, including four methyl groups, five  $\text{sp}^3$  methylene groups, one  $\text{sp}^2$  methine, two  $\text{sp}^3$  methine groups and four quaternary carbons (three oxygenated carbons). The above information accounted for two degrees of unsaturation, indicating one cyclic system in compound **4**. The  $^1\text{H}$ - $^1\text{H}$  COSY spectrum revealed two spin systems: (a) H-5/H-6/H-1/H-2/H-3 and (b) H-8/H-9/H-10 (Figure 2). Furthermore, the HMBC correlations from H<sub>3</sub>-15 ( $\delta_{\text{H}}$  1.04) to C-3/C-5; from H<sub>2</sub>-2 ( $\delta_{\text{H}}$  1.59, 1.53)/H<sub>2</sub>-6 ( $\delta_{\text{H}}$  1.29) to C-7; from H<sub>3</sub>-14 ( $\delta_{\text{H}}$  0.96) to C-1/C-8; from H-10 ( $\delta_{\text{H}}$  6.71) to

C-8/C-12/C-13; from H<sub>3</sub>-13 ( $\delta_{\text{H}}$  1.77) to C-11/C-12 and from H<sub>3</sub>-16 ( $\delta_{\text{H}}$  3.64) to C-12 made those two spin systems connected. Thus, the planar structure of **4** was established as shown (Figure 1) and named fallopiaxylarol A.

Initially, the ROESY correlation between H<sub>3</sub>-13 and H<sub>2</sub>-9 and the lack of correlation of H<sub>3</sub>-13/H-10 assigned the *E*-geometry of  $\Delta^{10,11}$ , which was also supported by the *J* value of H-10 (7.5) (Figure 5). Besides, the ROESY correlations of H-1/3-OH/H<sub>3</sub>-15/H-5 $\alpha$ /H-6 $\alpha$  suggested the *cis* orientation of the H-1, 3-OH, and H<sub>3</sub>-15. Furthermore, the literature survey revealed that the NMR data of the six-membered ring and the optical rotation values of **4** were almost identical to those of (1*S*,3*R*,4*R*,7*S*)-3,4-dihydroxy- $\alpha$ -bisabolol [16]. Thus, the absolute configuration of **4** was tentatively determined as shown in Figure 1.

**Table 4.**  $^1\text{H}$  NMR ( $\delta_{\text{H}}$ , 600 MHz) and  $^{13}\text{C}$  NMR ( $\delta_{\text{C}}$ , 150 MHz) data for **4**.

No.	$\delta_{\text{H}}$ , mult (J Hz) <sup>a</sup>	$\delta_{\text{C}}$ , Type <sup>a</sup>	$\delta_{\text{H}}$ , mult (J Hz) <sup>b</sup>	$\delta_{\text{C}}$ , Type <sup>b</sup>
1	1.72, m	39.1, CH	1.59, m, overlap	38.8, CH
2	1.80, m	29.3, CH <sub>2</sub>	1.59, m, overlap	29.2, CH <sub>2</sub>
3	3.66, br s	74.0, CH	3.36, m, overlap	72.6, CH
4		70.9, C		69.5, C
5	1.74, m	33.6, CH <sub>2</sub>	1.49, m	33.5, CH <sub>2</sub>
	1.55, m		1.29, m, overlap	
6	1.49, m	22.1, CH <sub>2</sub>	1.29, m, overlap	21.7, CH <sub>2</sub>
	1.40, m			
7		74.0, C		72.0, C
8	1.60, m	38.8, CH <sub>2</sub>	1.41, m	38.1, CH <sub>2</sub>
9	2.26, m	22.9, CH <sub>2</sub>	2.18, q (8.0)	22.7, CH <sub>2</sub>
10	6.77, td (7.5, 1.2)	142.6, CH	6.71, td (7.5, 0.9)	143.5, CH
11		127.6, C		126.4, C
12		168.8, C	0.90, t (6.8)	167.7, C
13	1.84, s	12.4, CH <sub>3</sub>	1.77, s	12.2, CH <sub>3</sub>
14	1.14, s	23.7, CH <sub>3</sub>	0.96, s	23.8, CH <sub>3</sub>
15	1.26, s	27.6, CH <sub>3</sub>	1.04, s	27.9, CH <sub>3</sub>
16	3.73, s	51.8, CH <sub>3</sub>	3.64, s	51.6, CH <sub>3</sub>
3-OH			4.36, d (4.0)	
4-OH			3.96, s	
7-OH			3.88, s	

<sup>a</sup>Measured in chloroform-*d*, <sup>b</sup>measured in DMSO-*d*<sub>6</sub>.

After literature survey, as for the secondary metabolites produced by the genus *Xylaria*, the main structural differences between the co-isolated new pyranone derivatives in this case and the other analogues of the genus are the variation of substituents in the side chain attached pyranone core [7,12,16]. Although compound **5** has previously been reported as a natural product from fermentation extracts of endophytic fungi [17], this is the first report of its existence to be accompanied by a full suite of supporting spectroscopic data. The fourteen known compounds, pestalotiopyrone M (**5**), 4-methoxy-6-nonyl-2-pyrone (**6**) [18], xylariaopyprone A (**7**) [19], xylariaopyprone H (**8**) [12], xylariaopyprone I (**9**) [12], xylapyrone D (**10**) [20], scirpyrone H (**11**) [21], 1*α*,10*α*-epoxy-3*α*,13-dihydroxyeremophil-7(11)-en-12,8*β*-olide (**12**) [4], 3*α*-hydroxymairetolid A (**13**) [4], mairetolid A (**14**) [22], (−)-5-methylmellein (**15**) [23], diaporthin (**16**) [24], mucorisocoumarin B (**17**) [25], eucalyptene (**18**) [26], were also isolated from *Xylaria* sp. Z184. The structures of these compounds (**5–18**) were identified by comparing the spectral data to those reported in the respective references.

Given the secondary metabolites generated by stains of *Xylaria* usually show obvious anti-inflammatory and antifungal activities [7,8]. In this case, compounds **2–10** and **15–18** and the crude extract were selected to evaluate the antimicrobial, anti-inflammatory and  $\alpha$ -glucosidase inhibition activities due to the limitation of samples. In antimicrobial assay, compounds **5**, **7**, and **8** displayed

weak activity against *Staphylococcus aureus* subsp. *aureus* with inhibition ratios of 25.9%, 31.5% and 25.3% at a concentration of 100  $\mu$ M. Unfortunately, in anti-inflammatory and  $\alpha$ -glucosidase assay, only the crude extract potently inhibited LPS-induced NO production in RAW264.7 mouse macrophages, with an inhibition rate of  $77.28 \pm 0.82\%$  at a concentration of 50  $\mu$ g/mL, although it was cytotoxic at this concentration, reducing the concentration to 6.25  $\mu$ M abrogated the cytotoxicity (Table 5).

**Table 5.** Inhibitory activities of compounds selected and crude extract on LPS-stimulated NO production.

Compounds	Concentration	NO production inhibition (%) <sup>a</sup>
<b>2</b>	50 $\mu$ M	$4.51 \pm 0.35$
<b>3</b>	50 $\mu$ M	$-3.93 \pm 2.43$
<b>4</b>	50 $\mu$ M	$1.85 \pm 3.18$
<b>5</b>	50 $\mu$ M	$-1.61 \pm 0.53$
<b>12</b>	50 $\mu$ M	$0.92 \pm 2.97$
<b>13</b>	50 $\mu$ M	$4.67 \pm 2.36$
<b>14</b>	50 $\mu$ M	$3.54 \pm 1.26$
<b>18</b>	50 $\mu$ M	$-0.92 \pm 2.21$
<b>Crude extract</b>	50 $\mu$ g/mL	<b><math>77.28 \pm 0.82</math></b>
	6.25 $\mu$ g/mL	<b><math>7.78 \pm 3.29</math></b>
<b>L-NMMA<sup>b</sup></b>	50 $\mu$ M	$53.75 \pm 1.28$

<sup>a</sup>All compounds examined in a set of triplicated experiment. <sup>b</sup>Positive control.

### 3. Materials and Methods

#### 3.1. General Experimental Procedures

Optical rotations were determined with a PerkinElmer 341 polarimeter (PerkinElmer, Waltham, MA, USA). UV absorptions were obtained by using a Waters UV-2401A spectrophotometer equipped with a DAD and a 1 cm path length cell. Methanolic samples were scanned from 190 to 400 nm in 1 nm steps. Measurements of IR spectra were performed using a Bruker Vertex 70 FT-IR spectrometer (Bruker, Karlsruhe, Germany). NMR spectra were recorded on Bruker AM-400 and AM-600 NMR spectrometers (Bruker, Karlsruhe, Germany) with TMS as internal standard, and NMR data were referenced to selected chemical shifts of methanol-*d*4 ( $^1\text{H}$ : 3.31 ppm,  $^{13}\text{C}$ : 49.0 ppm), chloroform-*d* ( $^1\text{H}$ : 7.26 ppm,  $^{13}\text{C}$ : 77.0 ppm) and dimethyl sulfoxide-*d*6 ( $^1\text{H}$ : 2.50 ppm,  $^{13}\text{C}$ : 39.5 ppm), respectively. HRESIMS data were acquired on a Thermo Fisher LTQ XL LC/MS (Thermo Fisher, Palo Alto, CA, USA). Semi-preparative HPLC was performed on an Agilent 1220 instrument equipped with a UV detector with a semi-preparative column (RP-C<sub>18</sub>, 5  $\mu$ m, 250  $\times$  10 mm, Welch Materials, Inc.). Column chromatography was performed using Sephadex<sup>TM</sup> LH-20 gel (40–70  $\mu$ m; Merck KGaA, Darmstadt, Germany), and precoated silica gel plates (GF254, Qingdao Marine Chemical Co. Ltd., Qingdao) were used for TLC analyses. Spots were visualized by heating silica gel plates sprayed with 10%  $\text{H}_2\text{SO}_4$  in EtOH. All HPLC solvents were purchased from Guangdong Guanghua Sci-Tech Co. Ltd (Guangzhou, China). All solvents were of analytical grade (Guangzhou Chemical Regents Company, Ltd., Guangzhou, China).

#### 3.2. Fungal Material

The fungus *Xylaria* sp. Z184 was isolated from the leaves of *Fallopia convolvulus* (L.)  $\ddot{\text{A}}$ . Löve collected in Zhuyang Town, Henan province, P. R. China (N 34°14'12" W 110°47'09") in June 2022. Leaves of *F. convolvulus* (L.)  $\ddot{\text{A}}$ . Löve were processed within 24 hours and rinsed with sterile water. On a sterile workbench, after 30 minutes of ultraviolet light exposure, the leaves underwent sequential treatment with a 5% sodium hypochlorite solution, sterile water, and 75% ethanol, either soaked or rinsed, followed by drying with sterile filter paper. Leaves were trimmed into small

squares with sterile scissors and placed into previously prepared PDA monoclonal agar plates, inoculating three petri plates in parallel. These plates were incubated at 30 °C for 3–7 days, until mycelial growth was observed extending from the inside of the tissue block to its surroundings. Distinct morphological colonies were subsequently transferred to new media for continued cultivation. This procedure was repeated until the fungal strains showed uniform growth, leading to the isolation of purified strains.

To identify the strains, the standardized operating procedure was performed, which included genomic DNA extraction, 16S/18S amplification, PCR product detection and purification, and comparison of sequencing results with the NCBI-BLAST database (<https://www.ncbi.nlm.nih.gov/>), using ITS1 and ITS4 primers for both amplification and sequencing. The sequence data for this strain was submitted to the GenBank under accession No. KU645984. The fungal strain was deposited on 20% aqueous glycerol stock in a -80 °C freezer at the School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.



**Figure 6.** Photo of the fungus *Xylaria* sp. Z184.

### 3.3. Fermentation, Extraction and Isolation

*Xylaria* sp. Z184 was cultured on potato dextrose agar for 5 days at 28 °C to prepare the seed culture. The cultured agar plates were cut into small pieces, which were then inoculated into 30 previously-autoclaved Erlenmeyer flasks (350 mL), each containing 50 g of rice and 45 mL of distilled water. All flasks were incubated at 28 °C for 40 days. Cultural media was extracted with methanol four times, and the solvent was evaporated under reduced pressure at 45 °C. Then the extract was suspended in water and extracted four times with ethyl acetate. The combined ethyl acetate layers were concentrated under reduced pressure to yield a brown extract (7.5 g).

The crude extract was chromatographed on Sephadex LH-20 (MeOH) to give eight fractions (Fr.1–Fr.8). Fr. 3 (2.8 g) was separated with silica gel column chromatography (CC) with petroleum ether (PE)/EtOAc (20:1–0:1, v/v) to give seven subfractions (Fr. 3.1–Fr. 3.7). Fr. 3.3 (306.2 mg) was purified with silica gel CC using PE/EtOAc (15:1–1:1, v/v) to yield six further subfractions (Fr. 3.3.1–Fr. 3.3.6). Fr. 3.3.4 (25.8 mg) was purified by semi-preparative HPLC (MeOH/H<sub>2</sub>O, 48:52, v/v, 3.0 mL/min) to yield compound 7 (4.3 mg, *t*<sub>R</sub> 22.0 min). Fr. 4 (1.7 g) was separated by silica gel CC with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (80:1–0:1, v/v) to obtain seven subfractions (Fr. 4.1–Fr. 4.7). Fr. 4.3 (277.5 mg) was purified by semi-preparative HPLC (MeCN/H<sub>2</sub>O, 25:75, 0–14 min, then MeCN/H<sub>2</sub>O, 50:50, 14.01–33 min, v/v, 3.0 mL/min) to yield compounds 13 (4.6 mg, *t*<sub>R</sub> 12.1 min), 14 (1.6 mg, *t*<sub>R</sub> 27.6 min), and 6 (4.1 mg, *t*<sub>R</sub> 31.5 min). Fr. 4.5 (239.9 mg) was purified by semi-preparative HPLC (MeCN/H<sub>2</sub>O, 20:80, 0–10 min, then MeCN/H<sub>2</sub>O, 40:60, 10.01–21 min, v/v, 3.0 mL/min) to yield compounds 10 (8.7 mg, *t*<sub>R</sub> 13.2 min) and 4 (6.0 mg, *t*<sub>R</sub> 19.5 min). Fr. 4.6 (225.9 mg) was purified by semi-preparative HPLC (MeOH/H<sub>2</sub>O, 40:60, v/v, 3.0 mL/min) to yield compounds 2 (3.9 mg, *t*<sub>R</sub> 30.1 min) and 3 (12.1 mg, *t*<sub>R</sub> 35.5 min). Fr. 5 (1.3 g) was separated with silica gel CC with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (25:1–0:1, v/v) to give six subfractions (Fr. 5.1 – Fr. 5.6). Fr. 5.1 (44.0 mg) was further purified by semi-preparative HPLC (MeOH/H<sub>2</sub>O, 55:45, 0–23 min, then MeOH/H<sub>2</sub>O, 65:35, 23.01–47 min, v/v, 3.0 mL/min) to yield compounds 15 (3.1 mg, *t*<sub>R</sub> 21.8 min) and 18 (1.4 mg, *t*<sub>R</sub> 45.5 min). Fr. 5.3 (399.7 mg) was purified by semi-preparative HPLC (MeOH/H<sub>2</sub>O, 35:65, 0–19 min, then MeOH/H<sub>2</sub>O, 54:46, 19.01–40 min, v/v, 3.0 mL/min) to yield compounds 1 (1.2 mg, *t*<sub>R</sub> 6.0 min), 17 (8.3 mg, *t*<sub>R</sub> 18.1 min), 16 (2.7 mg, *t*<sub>R</sub> 31.9 min), and 11 (2.4 mg, *t*<sub>R</sub> 38.2 min). Similarly, Fr. 5.4 (355.8 mg) was purified by semi-preparative HPLC (MeCN/H<sub>2</sub>O, 10:90, v/v, 3.0 mL/min) to yield compounds 5 (3.5 mg, *t*<sub>R</sub> 6.5 min), 8 (1.3 mg, *t*<sub>R</sub> 8.1 min), 9 (8.3 mg, *t*<sub>R</sub> 10.9 min), and 12 (2.1 mg, *t*<sub>R</sub> 15.5 min).

### 3.4. Spectral and Physical Data of Compounds 1–5

Fallopiaxylarester A (**1**): White solid;  $[\alpha]_D^{25} +56.2$  (*c* 0.11, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log \varepsilon$ ): 279 (0.19), 204 (0.72) nm; IR (KBr)  $\nu_{\max}$ : 3426, 2922, 1733, 1648, 1569, 1457, 1412, 1384, 1247, 1032, 832  $\text{cm}^{-1}$ ; ECD (MeOH)  $\lambda_{\max}$  ( $\Delta\varepsilon$ ): 279 (+3.0), 206 (−4.0) nm.  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, see Table 1; HRESIMS (*m/z*): 279.0837 [M + Na]<sup>+</sup> (calcd for  $\text{C}_{12}\text{H}_{16}\text{O}_6\text{Na}$ , 279.0839).

Fallopiaxylarester B (**2**): White solid;  $[\alpha]_D^{25} +102.9$  (*c* 0.38, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log \varepsilon$ ): 310 (0.16), 260 (0.06), 219 (0.41) nm; IR (KBr)  $\nu_{\max}$ : 3359, 2928, 2858, 1696, 1623, 1560, 1456, 1409, 1260, 1230, 1080, 1018, 817, 539  $\text{cm}^{-1}$ ; ECD (MeOH)  $\lambda_{\max}$  ( $\Delta\varepsilon$ ): 310 (+3.4), 231 (−4.1), 205 (−3.3) nm.  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, see Table 2; HRESIMS (*m/z*): 423.1626 [M + Na]<sup>+</sup> (calcd for  $\text{C}_{19}\text{H}_{28}\text{O}_9\text{Na}$ , 423.1626).

Fallopiaxylarester C (**3**): White solid;  $[\alpha]_D^{25} +124.2$  (*c* 0.39, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log \varepsilon$ ): 281 (0.11), 204 (0.45) nm; IR (KBr)  $\nu_{\max}$ : 3380, 2927, 2857, 1700, 1649, 1569, 1458, 1414, 1384, 1250, 1025, 836, 700  $\text{cm}^{-1}$ ; ECD (MeOH)  $\lambda_{\max}$  ( $\Delta\varepsilon$ ): 280 (+4.5), 232 (+0.9), 205 (+3.0) nm;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, see Table 3; HRESIMS (*m/z*): 425.1780 [M + Na]<sup>+</sup> (calcd for  $\text{C}_{19}\text{H}_{30}\text{O}_9\text{Na}$ , 425.1782).

Fallopiaxylarol A (**4**): Colorless oil;  $[\alpha]_D^{25} -31.8$  (*c* 0.10, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log \varepsilon$ ): 205 (0.36), 218 (0.48) nm; IR (KBr)  $\nu_{\max}$ : 3546, 3426, 2945, 2930, 1688, 1287, 1150, 1036  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, see Table 4; HRESIMS (*m/z*): 323.1829 [M + Na]<sup>+</sup> (calcd for  $\text{C}_{16}\text{H}_{28}\text{O}_5\text{Na}$ , 323.1829).

Pestalotiopyrone M (**5**): White solid; UV (MeOH)  $\lambda_{\max}$  nm ( $\log \varepsilon$ ) 206 (0.45), 293 (0.16); IR (KBr)  $\nu_{\max}$  3311, 2961, 2928, 1711, 1565, 1365, 1014, 989  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (methanol-*d*<sub>4</sub>, 600 MHz)  $\delta_{\text{H}}$ : 4.54 (2H, s, H-7), 4.41 (2H, s, H-8), 4.18 (3H, s, H-10), 2.35 (3H, s, H-9);  $^{13}\text{C}$  NMR (methanol-*d*<sub>4</sub>, 150 MHz)  $\delta_{\text{C}}$ : 171.6 (C, C-4), 167.4 (C, C-2), 163.0 (C, C-6), 115.2 (C, C-5), 110.1 (C, C-3), 63.1 (CH<sub>3</sub>, C-10), 55.5 (CH<sub>2</sub>, C-8), 55.1 (CH<sub>2</sub>, C-7), 17.3 (CH<sub>3</sub>, C-9); HRESIMS (*m/z*): 223.0578 [M + Na]<sup>+</sup> (calcd for  $\text{C}_9\text{H}_{12}\text{O}_5\text{Na}$ , 223.0577).

### 3.5. Computational Details (TDDFT-ECD) of **1**

The conformational search of (6*R*)-**1** was performed by using the torsional sampling (MCMM) conformational searches with OPLS\_2005 force field within an energy window of 21 kJ/mol. Conformers above 1% Boltzmann populations were re-optimized at the B3LYP/6-31G(d) level with the IEFPCM solvent model for methanol. The following TDDFT calculations of the re-optimized geometries were all performed at the B3LYP/6-311G(d,p) level with the IEFPCM solvent model for methanol. Frequency analysis was performed as well to confirm that the re-optimized geometries were at the energy minima. Finally, the SpecDis 1.62 [27] software was used to obtain the Boltzmann-averaged ECD spectra of **1** and visualize the result.

### 3.6. Biological Assays

#### 3.6.1. Antimicrobial Activity

Compounds **2–10** and **15–18**, and the crude extract were evaluated for antimicrobial activities against *Staphylococcus aureus* subsp. *aureus*, and fluconazole-resistant *Candida albicans*. The antimicrobial assay was conducted according to a previously-described method [28]. Samples were added into a 96-well culture plate with a maximum test compound concentration of 100  $\mu\text{M}$ . Bacterial liquid was added to each well until the final concentration was  $5 \times 10^5$  CFU/mL. The plate was then incubated at 37 °C for 24 h, and the OD values at 595 nm were measured using a microplate reader. Blank bacterial medium served as control.

#### 3.6.2. Anti-inflammatory Activity

The RAW 264.7 cells ( $2 \times 10^5$  cells/well) were incubated in 96-well culture plates with or without 1  $\mu\text{g}/\text{mL}$  lipopolysaccharide (LPS, Sigma Chemical Co., USA) for 24 h in the presence or absence of the test compounds. Supernatant aliquots (50  $\mu\text{L}$ ) were then treated with 100  $\mu\text{L}$  Griess reagent (Sigma Chemical Co., USA). The absorbance was measured at 570 nm by using a Synergy TMHT microplate reader (BioTek Instruments Inc., USA). In this study, N<sup>G</sup>-methyl-L-arginine acetate (L-NMMA, Sigma Chemical Co., USA) was used as a positive control. In the remaining medium, an MTT assay was carried out to determine whether the suppressive effect was related to cell viability. The inhibitory rate of nitric oxide (NO) production = (NO level of blank control – NO level of test samples)/NO level of blank control. The percentage of NO production was evaluated by measuring

the amount of nitrite concentration in the supernatants with Griess reagent, as described previously [29].

### 3.6.3. Alpha-Glucosidase Inhibition Activity

The  $\alpha$ -glucosidase inhibition was assessed according to the slightly modified method of Ma *et al* [30]. All samples were dissolved in DMSO at a concentration of 50  $\mu$ M. The  $\alpha$ -glucosidase (Sigma Chemical Co., USA) and substrate (4-Nitrophenyl  $\alpha$ -D-glucopyranoside, PNPG, Sigma Chemical Co., USA) were dissolved in potassium phosphate buffer (0.1 M, pH 6.7). The samples were preincubated with  $\alpha$ -glucosidase at 37 °C for 10 min. Then, PNPG was quickly added to the 96-well enzyme label plate to start the reaction, and the plate was incubated at 37 °C for 50 min. At the same time, a blank control without samples and a positive control of quercetin (10 mM) were set up. All samples were thoroughly mixed and analyzed in triplicate. The OD value was measured at 405 nm using a microplate reader. The inhibition percentage (%) was calculated by the following equation: Inhibition (%) = (1 - OD<sub>sample</sub>)/OD<sub>control blank</sub> × 100.

## 4. Conclusion

In this paper, three new pyranone derivatives (**1–3**) and a new bisabolane-type sesquiterpenoid (**4**) were discovered from the fungus *Xylaria* sp. Z184. Moreover, we co-isolated 14 previously-reported compounds (**5–18**), and reported the first complete set of spectroscopic data for pyranone **5**. *In vitro* bioassays were performed with a number of the isolated compounds and crude fungal extract. Compounds **5**, **7**, and **8** were demonstrated to be weak growth inhibitors of *Staphylococcus aureus* subsp. *Aureus*, and the extract was shown to be a potent inhibitor of NO production in LPS-stimulated RAW 264.7 mouse macrophages, with an inhibition rate of 77.28 ± 0.82% at 50  $\mu$ g/mL. Although the crude fungal extract showed certain inhibitory activity of NO production in LPS-stimulated RAW 264.7 mouse macrophages. Unfortunately, in the subsequent isolated compounds, no such convenient activity was found, which suggested that there may still be other structural types of compounds in the extract that exhibit anti-inflammatory activity. Anyway, in addition to revealing four novel compounds, this work enhances understanding of the structural diversity within the *Xylaria* metabolomes.

**Supplementary Materials:** The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figures S1–S79: 1D, 2D NMR spectra and HRESIMS of compounds **1–5**.

**Author Contributions:** Yan Zhang carried out the isolation and data curation at leading degree. Yang Jin conducted the writing of original draft. Wensi Yan was responsible for fungal isolation, fermentation, and identification of the samples. Peishan Gu, and Ziqian Zeng contributed to data curation and analysis at supporting degree. Ziyi Li, Guangtao Zhang, and Mi Wei contributed to the evaluation of antimicrobial activity. Yongbo Xue contributed to funding acquisition and project administration at leading degree. All authors read and approved the final manuscript.

**Funding:** This work was financially supported by the National Natural Science Foundation of China (No. 21977120 and 32270296), and the Key Basic Research Program of the Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20200109142215045).

**Acknowledgments:** The authors thank Dr. Xiaonian Li, Jianchao Chen, and the Shenzhen Bay Laboratory for their helpful assistance in NMR measurement. And we express our sincere thanks to Kunming Institute of Botany, Chinese Academy of Sciences for providing support in quantum chemical calculation.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The authors declare that all relevant data supporting the results of this study are available within in the article and its Supplementary Materials file.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds are not available from the authors.

## References

1. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J. Nat. Prod.* **2020**, *83*, 770–803.
2. Liu, H.; Tan, H.; Chen, Y.; Guo, X.; Wang, W.; Guo, H.; Liu, Z.; Zhang, W. Cytorhizins A-D, four highly structure-combined benzophenones from the endophytic fungus *Cytospora rhizophorae*. *Org. Lett.* **2019**, *21*, 1063–1067.
3. Han, W.B.; Wang, G.Y.; Tang, J.J.; Wang, W.J.; Liu, H.; Gil, R.R.; Navarro-Vázquez, A.; Lei, X.X.; Gao, J.M. Herpotrichones A and B, two intermolecular [4+2] adducts with anti-neuroinflammatory activity from a *Herpotrichia* Species. *Org. Lett.* **2020**, *22*, 405–409.
4. Yoiprommarat, S.; Unagul, P.; Suvannakad, R.; Klaysuban, A.; Suetrong, S.; Bunyapaiboonsri, T. Eremophilane sesquiterpenes from the mangrove fungus BCC 60405. *Phytochem. Lett.* **2019**, *34*, 84–90.
5. Wu, W.; Dai, H.; Bao, L.; Ren, B.; Lu, J.; Luo, Y.; Guo, L.; Zhang, L.; Liu, H. Isolation and structural elucidation of proline-containing cyclopentapeptides from an endolichenic *Xylaria* sp. *J. Nat. Prod.* **2011**, *74*, 1303–1308.
6. Xu, K.; Li, R.; Zhu, R.; Li, X.; Xu, Y.; He, Q.; Xie, F.; Qiao, Y.; Luan, X.; Lou, H. Xylarins A-D, two pairs of diastereoisomeric isoindoline alkaloids from the endolichenic fungus *Xylaria* sp. *Org. Lett.* **2021**, *23*, 7751–7754.
7. Chen, W.; Yu, M.; Chen, S.; Gong, T.; Xie, L.; Liu, J.; Bian, C.; Huang, G.; Zheng, C. Structures and biological activities of secondary metabolites from *Xylaria* spp. *J. Fungi.* **2024**, *10*, 190.
8. Han, W.B.; Zhai, Y.J.; Gao, Y.; Zhou, H.Y.; Xiao, J.; Pescitelli, G.; Gao, J.M. Cytochalasins and an abietane-type diterpenoid with allelopathic activities from the endophytic fungus *Xylaria* species. *J. Agric. Food. Chem.* **2019**, *67*, 3643–3650.
9. Jia, S.; Li, J.; Li, J.; Su, X.; Li, X.N.; Yao, Y.; Xue, Y. Anti-neuroinflammatory activity of new naturally occurring benzylated hydroxyacetophenone analogs from the endophytic fungus *Alternaria* sp. J030. *Chem. Biodivers.* **2022**, *19*, e202200751.
10. Jia, S.; Su, X.; Yan, W.; Wu, M.; Wu, Y.; Lu, J.; He, X.; Ding, X.; Xue, Y. Acorenone C: a new spirosesquiterpene from a mangrove-associated fungus, *Pseudofusicoccum* sp. J003. *Front. Chem.* **2021**, *9*, 780304.
11. Wu, Y.; Su, X.; Lu, J.; Wu, M.; Yang, S.Y.; Mai, Y.; Deng, W.; Xue, Y. *In Vitro* and *in silico* analysis of phytochemicals from *Fallopia dentataalata* as dual functional cholinesterase inhibitors for the treatment of Alzheimer's disease. *Front. Pharmacol.* **2022**, *13*, 905708.
12. Yang, W.W.; Lu, L.W.; Zhang, X.Q.; Bao, S.S.; Cao, F.; Guo, Z.Y.; Deng, Z.S.; Proksch, P. Xylariaopyrones E-I, five new  $\alpha$ -pyrone derivatives from the endophytic fungus *Xylariales* sp. (HM-1). *Nat. Prod. Res.* **2022**, *36*, 2230–2238.
13. Yamamoto, I.; Tai, A.; Fujinami, Y.; Sasaki, K.; Okazaki, S. Synthesis and characterization of a series of novel monoacylated ascorbic acid derivatives, 6-O-Acyl-2-O- $\alpha$ -D-glucopyranosyl-L-ascorbic acids, as skin antioxidants. *J. Med. Chem.* **2002**, *45*, 462–468.
14. Zhao, Q.; Wang, C.X.; Yu, Y.; Wang, G.Q.; Zheng, Q.C.; Chen, G.D.; Lian, Y.Y.; Lin, F.; Guo, L.D.; Gao, H. Nodulisporipyrone A-D, new bioactive  $\alpha$ -pyrone derivatives from *Nodulisporium* sp. *J. Asian Nat. Prod. Res.* **2015**, *17*, 567–575.
15. Lichtenhaller, F.W.; Martin, D.; Weber, T.; Schiweck, H. Studies on Ketoses, 7-5-( $\alpha$ -D-Glucosyloxymethyl)furfural: preparation from isomaltulose and exploration of its ensuing chemistry. *Eur. J. Org. Chem.* **1993**, *9*, 967–974.
16. Miyazawa, M.; Nankai, H.; Kameoka, H. Biotransformation of (–)- $\alpha$ -bisabolol by plant pathogenic fungus, *Glomerella cingulata*. *Phytochemistry* **1995**, *40*, 69–72.
17. Xu, J. The preparation method and application of a pyranoid compound with immunosuppressive activity. CN 108913731. **2018**.
18. Cook, L.; Ternai, B.; Ghosh, P. Inhibition of human sputum elastase by substituted 2-pyrone. *J. Med. Chem.* **1987**, *30*, 1017–1023.
19. Guo, Z.Y.; Lu, L.W.; Bao, S.S.; Liu, C.X.; Deng, Z.S.; Cao, F.; Liu, S.P.; Zou, K.; Proksch, P. Xylariaopyrones A-D, four new antimicrobial  $\alpha$ -pyrone derivatives from endophytic fungus *Xylariales* sp. *Phytochem. Lett.* **2018**, *28*, 98–103.
20. Zhang, H.; Deng, Z.; Guo, Z.; Peng, Y.; Huang, N.; He, H.; Tu, X.; Zou, K. Effect of culture conditions on metabolite production of *Xylaria* sp. *Molecules* **2015**, *20*, 7940–7950.
21. Tian, J.F.; Yu, R.J.; Li, X.X.; Gao, H.; Guo, L.D.; Tang, J.S.; Yao, X.S.  $^1$ H and  $^{13}$ C NMR spectral assignments of 2-pyrone derivatives from an endophytic fungus of *sarcosomataceae*. *Magn. Reson. Chem.* **2015**, *53*, 866–871.
22. Pérez-Castorena, A.L.; Arciniegas, A.; Guzmán, S.L.; Villaseñor, J.L.; Vivar, A.R. Eremophilanes from *Senecio mairetianus* and some reaction products. *J. Nat. Prod.* **2006**, *69*, 1471–1475.
23. Arora, D.; Sharma, N.; Singamaneni, V.; Sharma, V.; Kushwaha, M.; Abrol, V.; Guru, S.; Sharma, S.; Gupta, A.P.; Bhushan, S.; Jaglan, S.; Gupta, P. Isolation and characterization of bioactive metabolites from *Xylaria psidii*, an endophytic fungus of the medicinal plant *Aegle marmelos* and their role in mitochondrial dependent apoptosis against pancreatic cancer cells. *Phytomedicine* **2016**, *23*, 1312–1320.

24. Hallock, Y.F.; Clardy, J.; Kenfield, D.S.; Strobel, G. De-O-methyldiaporthin, a phytotoxin from *Drechslera siccans*. *Phytochemistry* **1988**, *27*, 3123–3125.
25. Feng, C.C.; Chen, G.D.; Zhao, Y.Q.; Xin, S.C.; Li, S.; Tang, J.S.; Li, X.X.; Hu, D.; Liu, X.Z.; Gao, H. New isocoumarins from a cold-adapted fungal strain *Mucor sp.* and their developmental toxicity to zebrafish embryos. *Chem. Biodivers.* **2014**, *11*, 1099–1108.
26. Lin, Y.; Wu, X.; Feng, S.; Jiang, G.; Zhou, S.; Vrijmoed, L.L.P.; Jones, E.B.G. A novel N-cinnamoylcyclopeptide containing an allenic ether from the fungus *Xylaria* sp. (strain #2508) from the South China Sea. *Tetrahedron Lett.* **2001**, *42*, 449–451.
27. Bruhn, T.; Schaumloffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the Comparison of Calculated and Experimental Electronic Circular Dichroism Spectra. *Chirality* **2013**, *25*, 243–249.
28. Zhang, N.; Shi, Z.; Guo, Y.; Xie, S.; Qiao, Y.; Li, X.N.; Xue, Y.; Luo, Z.; Zhu, H.; Chen, C.; Hu, L.; Zhang, Y. The absolute configurations of hyperilongenols A–C: rare 12,13-seco-spirocyclic polycyclic polyprenylated acylphloroglucinols with enolizable  $\beta$ ,  $\beta'$ -tricarbonyl systems from *Hypericum longistylum* Oliv. *Org. Chem. Front.* **2019**, *6*, 1491–1502.
29. Wu, Y.; Xie, S.; Hu, Z.; Wu, Z.; Guo, Y.; Zhang, J.; Wang, J.; Xue, Y.; Zhang, Y. Triterpenoids from whole plants of *Phyllanthus urinaria*. *Chinese Herb. Med.* **2017**, *9*, 193–196.
30. Ma, Y.Y.; Zhao, D.G.; Zhou, A.Y.; Zhang, Y.; Du, Z.; Zhang, K.  $\alpha$ -Glucosidase inhibition and antihyperglycemic activity of phenolics from the flowers of *Edgeworthia gardneri*. *J. Agric. Food. Chem.* **2015**, *63*, 8162–8169.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.